-
Pyrazoline B Induces Oxidative Stress Mediated Toxicity, Cell Cycle Arrest, and Caspase-Independent Apoptosis in BT-474 Human Breast Cancer Cells
13 Dec 2025 10:08 GMT
… A breast cancer cells, 4T1 and Hs578T triple-negative breast cancer (TNBC … . Since luminal B breast cancers tend to grow faster … The differential sensitivity across breast cancer subtypes is particularly interesting … AN, Rose PG. Abraxane for the treatment of …
-
<![CDATA[First-Line Sacituzumab Govitecan After Endocrine Therapy Fails to Improve PFS in HR+/HER2-Negative Breast Cancer ]]>
07 Nov 2025 17:32 GMT
… , HER2-negative metastatic breast cancer, missing the primary … situ hybridization) metastatic breast cancer who had received … or nab-paclitaxel (Abraxane). Treatment continued until disease … , HER2-negative metastatic breast cancer.
Sacituzumab govitecan is …
-
<![CDATA[TROPION-Breast02 Data Support Dato-DXd as New First-line SOC in Triple-Negative Breast Cancer]]>
20 Oct 2025 18:01 GMT
… inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy … form of paclitaxel, nab-paclitaxel (Abraxane), capecitabine, eribulin mesylate/ … inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy …
-
<![CDATA[OncLive Polls Highlight Top Votes on Anticipated Breast Cancer Abstracts at ESMO 2025]]>
03 Oct 2025 20:32 GMT
… 28-day cycle; nab-paclitaxel (Abraxane) at 100 mg/m2 … ) following surgery in participants with breast cancer (monarchE). ClinicalTrials.gov. Updated April … inoperable or metastatic triple-negative breast cancer (ASCENT-03). ClinicalTrials.gov. Updated …
-
Trastuzumab Deruxtecan Approved in Japan for HER2-Low or -Ultralow Metastatic Breast Cancer
26 Aug 2025 22:28 GMT
… with hormone receptor–positive metastatic breast cancer, including those who were HER2 … have included capecitabine, nab-paclitaxel (Abraxane), or paclitaxel. They were … low or HER2-ultralow metastatic breast cancer following disease progression after …
-
Platelet Membrane-Coated Poly (Lactic-Co-Glycolic Acid) Nanoparticles as a Targeting Drug Delivery System for Multidrug-Resistant Breast Cancer
01 Jul 2025 22:18 GMT
… alternative formulations such as Abraxane® (albumin-bound PTX … of multidrug-resistant breast cancer. The mechanism involves …
Human breast cancer cell (MCF-7) and breast cancer resistance … sensitive and multidrug-resistant breast cancer cells. Furthermore, …
-
T-DXd Improves All Outcomes in Post-Hoc Look of DESTINY-Breast06 in HR+, HER2-Low/-Ultralow Metastatic Breast Cancer
15 May 2025 21:24 GMT
… (Xeloda) or taxane (nab-paclitaxel [Abraxane] or paclitaxel) as second- or … -low or HER2-ultralow metastatic breast cancer, according to additional data from … identify patients with HER2-ultralow breast cancer.
Additional Trial Objectives, Findings, and …
-
Sacituzumab Govitecan-hziy Plus Pembrolizumab Improves PFS in Patients With Metastatic Triple-Negative Breast Cancer
24 Apr 2025 17:33 GMT
… -Myers Squibb], paclitaxel [Abraxane; Abraxis BioScience, LLC], … metastatic triple-negative breast cancer (ASCENT-04). … Navigating triple-negative breast cancer treatment with sacituzumab … navigating-triple-negative-breast-cancer-treatment-with-sacituzumab …
-
Anthracycline-Sparing Strategies Help Refine HER2+ Breast Cancer Management
17 Apr 2025 12:56 GMT
… management of HER2-positive breast cancer; highlighted the enduring … treatment for advanced HER2-positive breast cancer?
[When] talking [about] … for metastatic HER2-positive breast cancer, we have to … docetaxel, and nab-paclitaxel [Abraxane] was also an option …
-
T-DXd Wins EU Approval for HR+, HER2-Low or -Ultralow Metastatic Breast Cancer After Endocrine Therapy
04 Apr 2025 17:59 GMT
… receptor–positive metastatic breast cancers that express HER2,” … capecitabine, nab-paclitaxel (Abraxane), or paclitaxel.
PFS … of patients with metastatic breast cancer,” Dave Fredrickson, … HER2-ultralow metastatic breast cancer following disease progression …
About
© 1995-2026